Use access key #2 to skip to page content.
$26.75 -1.13 (-4.05%)
10/7/2008 3:45 PM

Vertex Pharmaceuticals, Inc. (VRTX)

CAPS Rating:
****

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

View All Commentary (VRTX)

Recs

0

Avatar riloburnham (44.95) Submitted: 4/24/08 9:38 PM : Outperform Start Price: $24.85 VRTX Score: 35.92

Vertex Pharmaceuticals Inc. released more positive data on its hepatitis C drug candidate telaprevir. The has declined recentley making it a good buy.
The stock fell $1.05, or 4.1 percent, to $24.90, adding to Wednesday's 3.8 percent decline. Shares have traded between $13.84 and $41.42 over the last 52 weeks.
Hepatitis C can cause liver disease and cancer and affects about 170 million people.

Report this Post Replies: 0 | Reply

Featured Broker Partners